| Target Price | $19.38 |
| Price | $19.59 |
| Deviation |
1.07%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target OptimizeRx Corporation 2026 .
The average OptimizeRx Corporation target price is $19.38.
This is
1.07%
register free of charge
$28.35
44.72%
register free of charge
$11.11
43.29%
register free of charge
|
|
| A rating was issued by 13 analysts: 11 Analysts recommend OptimizeRx Corporation to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the OptimizeRx Corporation stock has an average upside potential 2026 of
1.07%
register free of charge
|
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 92.13 | 108.64 |
| 28.82% | 17.92% | |
| EBITDA Margin | -2.05% | 14.94% |
| 90.30% | 828.27% | |
| Net Margin | -21.83% | 11.56% |
| 11.15% | 152.96% |
9 Analysts have issued a sales forecast OptimizeRx Corporation 2025 . The average OptimizeRx Corporation sales estimate is
This results in the following potential growth metrics:
9 Analysts have issued an OptimizeRx Corporation EBITDA forecast 2025. The average OptimizeRx Corporation EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 OptimizeRx Corporation Analysts have issued a net profit forecast 2025. The average OptimizeRx Corporation net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.10 | 0.68 |
| 6.80% | 161.82% | |
| P/E | 28.95 | |
| EV/Sales | 3.46 |
9 Analysts have issued a OptimizeRx Corporation forecast for earnings per share. The average OptimizeRx Corporation EPS is
This results in the following potential growth metrics and future valuations:
OptimizeRx Corporation...
| Analyst | Rating | Action | Date |
|---|---|---|---|
| JMP Securities |
Locked
➜
Locked
|
Locked | Oct 10 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Aug 11 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Aug 08 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | Jun 09 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | May 13 2025 |
| Stifel |
Locked
➜
Locked
|
Locked | May 13 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Feb 06 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
JMP Securities:
Locked
➜
Locked
|
Oct 10 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Aug 11 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Aug 08 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
Jun 09 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
May 13 2025 |
|
Locked
Stifel:
Locked
➜
Locked
|
May 13 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Feb 06 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


